Ultragenyx Pharmaceutical

August 07, 2018

Neuren pays the price for sellside froth

The Australian group has found a partner for its lead asset at last, so why is the stock down?

April 18, 2018

Ultragenyx picks a bold price tag for Crysvita

April 10, 2018

Where is the IPO class of 2014-15 now?

A golden age for biotech flotations yielded some spectacular blow-ups, but also saw several groups reward investors with premium-priced takeovers.

April 06, 2018

Upcoming events – Rare disease decisions for Ultragenyx and GW

February 23, 2018

EU thumbs-up sets the stage for burosumab’s more important test

January 23, 2018

Biotech gets creative about the pay cheque

Amid a backlash over the high prices of advanced therapies, biotech companies are coming up with new payment models.

December 22, 2017

Snippet roundup: Approvals for Merck/Pfizer and Biom Up, but Shire disappoints

December 15, 2017

Therapy focus – Antisense projects raise Huntington’s hopes

December 11, 2017

Ash 2017 – Spark extinguished by Biomarin haemophilia data